Impact of targeted antifungal prophylaxis in heart transplant recipients at high risk for early invasive fungal infection

Transplantation

Volumn 97, Issue 11, 2014, Pages 1192-1197

  Tissot, Frederic ^a   Pascual, Manuel ^a   Hullin, Roger ^a   Yerly, Patrick ^a   Tozzi, Piergiorgio ^a   Meylan, Pascal ^a   Manuel, Oriol ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

ECMO; Fungal infection.; Heart transplant

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BASILIXIMAB; CASPOFUNGIN; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; FLUCONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; VORICONAZOLE;

ADULT; AGED; ARTICLE; ASPERGILLUS; CANDIDA; CANDIDIASIS; EXTRACORPOREAL OXYGENATION; FEMALE; FUNGAL COLONIZATION; GRAFT RECIPIENT; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; LICHTHEIMIA CORYMBIFERA; LUNG ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MUCORMYCOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REOPERATION; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC MYCOSIS; TREATMENT DURATION; VENTRICULAR ASSIST DEVICE;

ANTIFUNGAL AGENTS; ASPERGILLUS; ECHINOCANDINS; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; HEART FAILURE; HEART TRANSPLANTATION; HOSPITALIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOSES; POSTOPERATIVE PERIOD; PROPORTIONAL HAZARDS MODELS; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902168077     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000441088.01723.ee     Document Type: Article

References (30)

1. Gurwith MJ, Stinson EB, Remington JS. Aspergillus infection complicating cardiac transplantation. Report of five cases. Arch Intern Med 1971; 128: 541.
2. Hofflin JM, Potasman I, Baldwin JC, et al. Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids. Ann Intern Med 1987; 106: 209.
3. Grossi P, Farina C, Fiocchi R, et al. Prevalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: a multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70: 112.
4. Montoya JG, Giraldo LF, Efron B, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001;33: 629.
5. Montoya JG, Chaparro SV, Celis D, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003; 37(Suppl 3): S281.
6. Munoz P, Guinea J, Pelaez T, et al. Nosocomial invasive aspergillosis in a heart transplant patient acquired during a break in the HEPA air filtration system. Transpl Infect Dis 2004; 6: 50.
7. Singh N, Paterson DL. Aspergillus infections in transplant recipients. Clin Microbiol Rev 2005; 18: 44.
8. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant- Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101.
9. Zaoutis TE, Webber S, Naftel DC, et al. Invasive fungal infections in pediatric heart transplant recipients: incidence, risk factors, and outcomes. Pediatr Transplant 2011; 15: 465.
10. Gavalda J, Len O, San Juan R, et al. Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case-control study. Clin Infect Dis 2005; 41: 52.
11. Singh N, Husain S, Practice ASTIDCo. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S180.
12. Munoz P, Rodriguez C, Bouza E, et al. Risk factors of invasive aspergillosis after heart transplantation: protective role of oral itraconazole prophylaxis. Am J Transplant 2004; 4: 636.
13. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503.
14. Singh N, Paterson DL, Gayowski T, et al. Preemptive prophylaxis with a lipid preparation of amphotericin B for invasive fungal infections in liver transplant recipients requiring renal replacement therapy. Transplantation 2001; 71: 910.
15. Ruiz S, Papy E, Da Silva D, et al. Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med 2009; 35: 183.
16. Eschertzhuber S, Velik-Salchner C, Hoermann C, et al. Caspofunginresistant Aspergillus flavus after heart transplantation and mechanical circulatory support: a case report. Transpl Infect Dis 2008; 10: 190.
17. Gardner AH, Prodhan P, Stovall SH, et al. Fungal infections and antifungal prophylaxis in pediatric cardiac extracorporeal life support. J Thorac Cardiovasc Surg 2012; 143: 689.
18. Sun HY, Ko WJ, Tsai PR, et al. Infections occurring during extracorporeal membrane oxygenation use in adult patients. J Thorac Cardiovasc Surg 2010; 140: 1125.
19. Kaplow LS, Goffinet JA. Profound neutropenia during the early phase of hemodialysis. JAMA 1968; 203: 1135.
20. Chervenick PA. Dialysis, neutropenia, lung dysfunction and complement. N Engl J Med 1977; 296: 810.
21. Losito A, Buoncristiani U, Cecchini C. Abnormal leucocyte locomotion induced by haemodialysis membranes. A clue to dialysis leucopenia. J Clin Lab Immunol 1983; 10: 87.
22. Zach TL, Steinhorn RH, Georgieff MK, et al. Leukopenia associated with extracorporeal membrane oxygenation in newborn infants. J Pediatr 1990; 116: 440.
23. Graulich J, Walzog B, Marcinkowski M, et al. Leukocyte and endothelial activation in a laboratory model of extracorporeal membrane oxygenation (ECMO). Pediatr Res 2000; 48: 679.
24. Hocker JR, Wellhausen SR, Ward RA, et al. Effect of extracorporeal membrane oxygenation on leukocyte function in neonates. Artif Organs1991; 15: 23.
25. Munoz P, Valerio M, Palomo J, et al. Targeted antifungal prophylaxis in heart transplant recipients. Transplantation 2013; 96: 664.
26. Dhar D, Dickson JL, Carby MR, et al. Fungal infection in cardiothoracic transplant recipients: outcome without systemic amphotericin therapy. Transpl Int 2012; 25: 758.
27. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008; 46: 327.
28. Aguado JM, Varo E, Usetti P, et al. Safety of anidulafungin in solid organ transplant recipients. Liver Transpl 2012; 18: 680.
29. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813.
30. Pappas PG, Silveira FP, Practice ASTIDCo. Candida in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S173.